<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230108057074N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-03-06</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Adjunctive effect of light therapy in some criteria on wound healing in burns patient</public_title>
      <acronym></acronym>
      <scientific_title>Adjunctive effect of light therapy in some criteria on wound healing in burns patient</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67929</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The samples are divided into intervention and control groups by random block allocation method. The total volume of the sample is divided into smaller groups that can be divided and an integer number is obtained, called blocks, so that inside each block there are four people from The sample volume is placed. Due to the fact that with a sample size of 30 and a block of 4, an integer number is not obtained, so the number 32 is considered. The placement of people (4 people) inside each block is imagined and recorded from the total sample size of the test and control group {(CACA)(CCAA)(ACCA)(ACAC)}. A number is assigned to each of these situations and recorded (CACA=4)(CCAA=3)(ACCA=2)(ACAC=1). The numbers are written on spherical objects of the same size and color and are thrown into the bag, and a person who is not in the work flow is asked to remove the objects from the bag for the required number of blocks, however repeated, and after Registering the number on the item, the item is returned to the bag. In this way, sampling is done according to the order of the blocks and the number taken out of the bag. It is necessary to explain that the previous block must be completed in order to complete the next block, Blinding description: The data gatherer and wound evaluator do not know اow to allocate groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>burn.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Bioptron light therapy device (Bioptron AG, Wollerau, Switzerland) from Mehrgan Tejarat Carmania Company, made in Switzerland, in accordance with EEC/93/42 light with wavelength characteristics of 480 to 3400 nm, polarization percentage 95%, power density 40 mW/cm2 and emits 4.2 J/cm2 energy per minute. Light irradiation will be daily for 6 minutes in 10 sessions, with a distance of 10 cm from the wound (13). If the patient is discharged before the completion of the light therapy sessions or the wound closure, follow-up will be done for the participant's daily visit until the wound is closed and the light therapy sessions are completed. Before each session, the wound will be opened and washed with saline. 0% will be washed. After the participant is in a comfortable position, the device will be placed towards the wound to shine the light. Then, according to the doctor's order, the usual treatment protocol for the wound will be implemented. Intervention 2: Control group: Control group: the wound will be exposed to the open air for 6 minutes, then according to the doctor's order, the usual treatment protocol for the wound will be implemented.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
We intend to publish it as an article

When:
We intend to publish it as an article

To whom:
We intend to publish it as an article

Conditions:
We intend to publish it as an article

Where to obtain:
We intend to publish it as an article

How to obtain:
We intend to publish it as an article

Comments:
We intend to publish it as an article</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ehsaneh Najari Ardestani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ale Mohammad Avenue</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8193661971</zip>
        <telephone>+98 31 3345 7670</telephone>
        <email>ehsanehnajari@mail.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ehsaneh Najari Ardestani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 22. Ale mohammad Ave. Esfahan</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8193661971</zip>
        <telephone>+98 31 3462 3648</telephone>
        <email>ehsanehnajari@mail.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patient with 18-60 years
total burn surface area 20%-40%
burn degree:2 partial thickness and full thickness
burn injury with scald</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of underlying disease, immune system disorders/blood circulation disorders/substance abuse and pregnancy
A history of taking blood thinners
The interval of more than 6 hours from the occurrence of burns to admission to the hospital
Presence of trauma in the wound
BMI less than 18.5 and more than 30</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T20-T32</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Burns and corrosions</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Bioptron light therapy device (Bioptron AG, Wollerau, Switzerland) from Mehrgan Tejarat Carmania Company, made in Switzerland, in accordance with EEC/93/42 light with wavelength characteristics of 480 to 3400 nm, polarization percentage 95%, power density 40 mW/cm2 and emits 4.2 J/cm2 energy per minute. Light irradiation will be daily for 6 minutes in 10 sessions, with a distance of 10 cm from the wound (13). If the patient is discharged before the completion of the light therapy sessions or the wound closure, follow-up will be done for the participant's daily visit until the wound is closed and the light therapy sessions are completed. Before each session, the wound will be opened and washed with saline. 0% will be washed. After the participant is in a comfortable position, the device will be placed towards the wound to shine the light. Then, according to the doctor's order, the usual treatment protocol for the wound will be implemented.</i_keyword>
      <i_keyword>Control group: Control group: the wound will be exposed to the open air for 6 minutes, then according to the doctor's order, the usual treatment protocol for the wound will be implemented.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Wound healing score. Timepoint: At the admission until the wound is closed, daily. Method of measurement: A photo will be taken of the patient's wound with a standard camera at a distance of 40 cm on a white background with sufficient light, and the evaluation form will be filled out daily for participation. will be completed.Wound healing parameters will be performed according to the standard method described by Monstrey et al., which includes edema of the burned area; type of wound discharge; the amount of wound discharge; type of necrotic tissue in the wound; amount of necrotic tissue in the wound; The degree of granulation of the wound and the degree of epithelization of the wound. Each parameter will be given a score from 1 to 5 according to the Likert scale. The wound evaluation form will be completed based on the photos taken by two plastic surgery specialists with more than 15 years of experience in the field of burns. A complete patient history without treatment details will be provided to the evaluators. Based on the photos taken of the wound, they will independently answer the questions in the wound evaluation section.</prim_outcome>
      <prim_outcome>Serum level of white blood cells. Timepoint: The review of paraclinical results will be based on the hospital protocol at the arrival of the patient and once every three days, and no other blood samples will be taken from the patient. Method of measurement: Based on the sample taken from the patient.</prim_outcome>
      <prim_outcome>The Vancouver Scar scale. Timepoint: In order to follow up after the first month, second month and sixth month after the end of the intervention, photographs will be taken of the light therapy site. To evaluate the scar, The Vancouver Scar scale will be used in 1, 3, and 6 months after the end of the intervention. Method of measurement: Using The Vancouver Scar scale at 1, 3, 6 months after the end of the intervention.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-09-12</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences,Isfahan,Iran Esfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
